Avadel Pharmaceuticals (AVDL)

• Market cap: $859M
• 1 day: 3.25%
• 5 days: 6.85%
• 1 month: 13.54%
• 3 months: 15.60%
• 6 months: -31.14%
• Year to date: -19.18%
• 1 year: -51.05%
• 5 years: -14.35%
• 10 years: -35.95%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Employees: 188

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

104% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $12.9M

70% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 40

4.92% more ownership

Funds ownership: 77.33% [Q3] → 82.24% (+4.92%) [Q4]

10% less funds holding

Funds holding: 175 [Q3] → 157 (-18) [Q4]

13% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]

15% less capital invested

Capital invested by funds: $976M [Q3] → $833M (-$143M) [Q4]

43% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 40

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 35% upside
• Avg. target: $17.33 95% upside
• High target: $21 136% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ami Fadia 22% 1-year accuracy 35 / 160 met price target	114% upside $19	Buy Reiterated	9 Apr 2025
HC Wainwright & Co. Oren Livnat 57% 1-year accuracy 28 / 49 met price target	136% upside $21	Buy Reiterated	4 Mar 2025
Deutsche Bank David Hoang 12% 1-year accuracy 2 / 17 met price target	35% upside $12	Buy Initiated	11 Feb 2025